| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:49 UTC |
|---|
| Update Date | 2022-03-07 02:51:38 UTC |
|---|
| HMDB ID | HMDB0014460 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Zolmitriptan |
|---|
| Description | Zolmitriptan is only found in individuals that have used or taken this drug. It is a synthetic tryptamine derivative and appears as a white powder that is readily soluble in water. [Wikipedia ]Zolmitriptan binds with high affinity to human 5-HT1B and 5-HT1D receptors leading to cranial blood vessel constriction. Current theories proposed to explain the etiology of migraine headache suggest that symptoms are due to local cranial vasodilatation and/or to the release of sensory neuropeptides (vasoactive intestinal peptide, substance P and calcitonin gene-related peptide) through nerve endings in the trigeminal system. The therapeutic activity of zolmitriptan for the treatment of migraine headache can most likely be attributed to the agonist effects at the 5HT1B/1D receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release. |
|---|
| Structure | CN(C)CCC1=CNC2=CC=C(C[C@H]3COC(=O)N3)C=C12 InChI=1S/C16H21N3O2/c1-19(2)6-5-12-9-17-15-4-3-11(8-14(12)15)7-13-10-21-16(20)18-13/h3-4,8-9,13,17H,5-7,10H2,1-2H3,(H,18,20)/t13-/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| 311c90 | ChEBI | | 4-[[3-(2-Dimethylaminoethyl)-1H-indol-5-yl]methyl]oxazolidin-2-one | ChEBI | | Zipton | ChEBI | | Zolmitriptanum | ChEBI | | Zomig | ChEBI | | Zomigoro | ChEBI | | Zominat | ChEBI | | ZMT | HMDB | | Ferrer brand OF zolmitriptan | HMDB | | AscoTop | HMDB | | Zeneca brand OF zolmitriptan | HMDB | | 4-((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone | HMDB | | AstraZeneca brand OF zolmitriptan | HMDB | | Flezol | HMDB | | Astra brand OF zolmitriptan | HMDB |
|
|---|
| Chemical Formula | C16H21N3O2 |
|---|
| Average Molecular Weight | 287.3568 |
|---|
| Monoisotopic Molecular Weight | 287.163376931 |
|---|
| IUPAC Name | (4S)-4-({3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one |
|---|
| Traditional Name | zomig |
|---|
| CAS Registry Number | 139264-17-8 |
|---|
| SMILES | CN(C)CCC1=CNC2=CC=C(C[C@H]3COC(=O)N3)C=C12 |
|---|
| InChI Identifier | InChI=1S/C16H21N3O2/c1-19(2)6-5-12-9-17-15-4-3-11(8-14(12)15)7-13-10-21-16(20)18-13/h3-4,8-9,13,17H,5-7,10H2,1-2H3,(H,18,20)/t13-/m0/s1 |
|---|
| InChI Key | ULSDMUVEXKOYBU-ZDUSSCGKSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as tryptamines and derivatives. Tryptamines and derivatives are compounds containing the tryptamine backbone, which is structurally characterized by an indole ring substituted at the 3-position by an ethanamine. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Indoles and derivatives |
|---|
| Sub Class | Tryptamines and derivatives |
|---|
| Direct Parent | Tryptamines and derivatives |
|---|
| Alternative Parents | |
|---|
| Substituents | - Tryptamine
- 3-alkylindole
- Indole
- Aralkylamine
- Oxazolidinone
- Substituted pyrrole
- Benzenoid
- Oxazolidine
- Pyrrole
- Heteroaromatic compound
- Carbamic acid ester
- Carbonic acid derivative
- Tertiary amine
- Tertiary aliphatic amine
- Oxacycle
- Azacycle
- Hydrocarbon derivative
- Organic oxide
- Organopnictogen compound
- Organooxygen compound
- Organonitrogen compound
- Organic oxygen compound
- Organic nitrogen compound
- Carbonyl group
- Amine
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.19 g/L | Not Available | | LogP | 1.6 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 4.85 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 9.9419 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 4.07 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 119.6 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 611.8 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 215.3 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 117.7 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 167.7 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 88.7 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 275.5 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 276.9 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 849.1 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 702.9 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 185.2 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1002.1 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 191.7 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 220.1 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 602.4 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 400.6 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 95.8 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Zolmitriptan,1TMS,isomer #1 | CN(C)CCC1=CN([Si](C)(C)C)C2=CC=C(C[C@H]3COC(=O)N3)C=C12 | 2769.8 | Semi standard non polar | 33892256 | | Zolmitriptan,1TMS,isomer #1 | CN(C)CCC1=CN([Si](C)(C)C)C2=CC=C(C[C@H]3COC(=O)N3)C=C12 | 2763.0 | Standard non polar | 33892256 | | Zolmitriptan,1TMS,isomer #1 | CN(C)CCC1=CN([Si](C)(C)C)C2=CC=C(C[C@H]3COC(=O)N3)C=C12 | 4039.5 | Standard polar | 33892256 | | Zolmitriptan,1TMS,isomer #2 | CN(C)CCC1=C[NH]C2=CC=C(C[C@H]3COC(=O)N3[Si](C)(C)C)C=C12 | 2711.3 | Semi standard non polar | 33892256 | | Zolmitriptan,1TMS,isomer #2 | CN(C)CCC1=C[NH]C2=CC=C(C[C@H]3COC(=O)N3[Si](C)(C)C)C=C12 | 2756.3 | Standard non polar | 33892256 | | Zolmitriptan,1TMS,isomer #2 | CN(C)CCC1=C[NH]C2=CC=C(C[C@H]3COC(=O)N3[Si](C)(C)C)C=C12 | 3558.8 | Standard polar | 33892256 | | Zolmitriptan,2TMS,isomer #1 | CN(C)CCC1=CN([Si](C)(C)C)C2=CC=C(C[C@H]3COC(=O)N3[Si](C)(C)C)C=C12 | 2712.2 | Semi standard non polar | 33892256 | | Zolmitriptan,2TMS,isomer #1 | CN(C)CCC1=CN([Si](C)(C)C)C2=CC=C(C[C@H]3COC(=O)N3[Si](C)(C)C)C=C12 | 2769.6 | Standard non polar | 33892256 | | Zolmitriptan,2TMS,isomer #1 | CN(C)CCC1=CN([Si](C)(C)C)C2=CC=C(C[C@H]3COC(=O)N3[Si](C)(C)C)C=C12 | 3267.7 | Standard polar | 33892256 | | Zolmitriptan,1TBDMS,isomer #1 | CN(C)CCC1=CN([Si](C)(C)C(C)(C)C)C2=CC=C(C[C@H]3COC(=O)N3)C=C12 | 2983.0 | Semi standard non polar | 33892256 | | Zolmitriptan,1TBDMS,isomer #1 | CN(C)CCC1=CN([Si](C)(C)C(C)(C)C)C2=CC=C(C[C@H]3COC(=O)N3)C=C12 | 2970.9 | Standard non polar | 33892256 | | Zolmitriptan,1TBDMS,isomer #1 | CN(C)CCC1=CN([Si](C)(C)C(C)(C)C)C2=CC=C(C[C@H]3COC(=O)N3)C=C12 | 4024.9 | Standard polar | 33892256 | | Zolmitriptan,1TBDMS,isomer #2 | CN(C)CCC1=C[NH]C2=CC=C(C[C@H]3COC(=O)N3[Si](C)(C)C(C)(C)C)C=C12 | 2921.4 | Semi standard non polar | 33892256 | | Zolmitriptan,1TBDMS,isomer #2 | CN(C)CCC1=C[NH]C2=CC=C(C[C@H]3COC(=O)N3[Si](C)(C)C(C)(C)C)C=C12 | 2979.2 | Standard non polar | 33892256 | | Zolmitriptan,1TBDMS,isomer #2 | CN(C)CCC1=C[NH]C2=CC=C(C[C@H]3COC(=O)N3[Si](C)(C)C(C)(C)C)C=C12 | 3549.5 | Standard polar | 33892256 | | Zolmitriptan,2TBDMS,isomer #1 | CN(C)CCC1=CN([Si](C)(C)C(C)(C)C)C2=CC=C(C[C@H]3COC(=O)N3[Si](C)(C)C(C)(C)C)C=C12 | 3105.1 | Semi standard non polar | 33892256 | | Zolmitriptan,2TBDMS,isomer #1 | CN(C)CCC1=CN([Si](C)(C)C(C)(C)C)C2=CC=C(C[C@H]3COC(=O)N3[Si](C)(C)C(C)(C)C)C=C12 | 3180.6 | Standard non polar | 33892256 | | Zolmitriptan,2TBDMS,isomer #1 | CN(C)CCC1=CN([Si](C)(C)C(C)(C)C)C2=CC=C(C[C@H]3COC(=O)N3[Si](C)(C)C(C)(C)C)C=C12 | 3333.9 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Zolmitriptan GC-MS (Non-derivatized) - 70eV, Positive | splash10-0a4i-9140000000-8d3d0029a006c9f3ba49 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Zolmitriptan GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Zolmitriptan , positive-QTOF | splash10-000i-1390000000-5eb2470575d7a40b35dd | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Zolmitriptan , positive-QTOF | splash10-000i-0390000000-d91f1c70da42e9043a7b | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Zolmitriptan 35V, Positive-QTOF | splash10-0a5l-4970000000-d6feef1af8c3d273bbe4 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Zolmitriptan 35V, Negative-QTOF | splash10-000i-0090000000-c74574aba82b34fbcfc1 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Zolmitriptan 10V, Positive-QTOF | splash10-000i-0090000000-2eab59f442a95263f917 | 2016-08-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Zolmitriptan 20V, Positive-QTOF | splash10-000l-1290000000-4b3bf33424e3bd5259dc | 2016-08-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Zolmitriptan 40V, Positive-QTOF | splash10-00du-2910000000-46170261887fb6bb2a86 | 2016-08-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Zolmitriptan 10V, Negative-QTOF | splash10-000i-2090000000-33a4ce8acdaace7f51cb | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Zolmitriptan 20V, Negative-QTOF | splash10-0006-9060000000-dc863874d2aa1113bab8 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Zolmitriptan 40V, Negative-QTOF | splash10-0006-9100000000-ee342e011f9a483f3bed | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Zolmitriptan 10V, Positive-QTOF | splash10-000i-2090000000-59447660b4ff1ee0d5a8 | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Zolmitriptan 20V, Positive-QTOF | splash10-0a4i-9170000000-ae1576ef07f3ffa1d131 | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Zolmitriptan 40V, Positive-QTOF | splash10-0a4i-9320000000-d3b22cc0b99199c251b7 | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Zolmitriptan 10V, Negative-QTOF | splash10-000i-0090000000-85a896e022373a149d53 | 2021-09-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Zolmitriptan 20V, Negative-QTOF | splash10-000l-0090000000-78d6b93aa92bfd05a777 | 2021-09-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Zolmitriptan 40V, Negative-QTOF | splash10-0006-5970000000-3b90408e256cd6d8ae19 | 2021-09-23 | Wishart Lab | View Spectrum |
|
|---|